

Thrombolysis of the Main Portal Vein with EKOS™

JASON SMITH, MD, Loma Linda Medical Center, Loma Linda, CA


Patient History

A 16-year-old male presented to emergency department with severe epigastric pain:


- Abdominal CT demonstrated complete thrombosis of portal vein (PV), splenic vein (SV) and superior mesenteric veins (SMV)
- Patient started on pain control and heparin drip, and was admitted
- A hypercoagulable work-up was instituted, and interventional radiology (IR) was consulted

Initial Endovascular Treatment


- Heparin drip was held, and patient brought to IR
- Percutaneous trans-hepatic access obtained with US guidance into right PV, and a vascular sheath placed. A device was manipulated into patent middle colic vein; venogram confirmed SMV and PV thrombosis
- 3000 units of heparin administered intravenously and mechanical thrombectomy performed with Angiojet (Possis) from peripheral to central several times
- EKOS™ (18 cm treatment length) device was placed across the SMV and main PV
- Through the right common femoral artery a diagnostic device placed with its tip in the superior mesenteric artery (SMA)
- 1mg/hour tPA infusions initiated in even split doses via EKOS™ and diagnostic devices
- 300 units/hour heparin infusions initiated in even split doses via sheaths




Initial portal venogram



Initial EKOS™ placement



Recanalization at 21 hour follow-up



Splenic arterial portogram at 41 hours

Thrombolysis of the Main Portal Vein with EKOS™

JASON SMITH, MD, Loma Linda Medical Center, Loma Linda, CA

Results

Patient brought back 21 hours after EKOS™ placement:

- Recanalization of superior SMV and PV, but with residual scattered non-occlusive thrombus
- Balloon angioplasty performed of the SMA and main PV
- EKOS™ device repositioned into SV, which remained thrombosed
- tPA and heparin infusions were continued overnight at same doses/rates
- Patient continued treatment with EKOS™ overnight

Follow-up at 41 hours after EKOS™ placement:

- Patient had hematuria overnight not requiring transfusion
- Completion angiograms demonstrated approximately 90% reduction in clot burden in portomesenteric veins, with robust hepatopetal flow
- Trans-hepatic sheath was removed and hemostasis achieved by tract embolization, and hemostasis was achieved at the groin puncture site with a percutaneous closure device placement

Conclusion

- Lovenox therapy was begun. The patient's hematuria and pain resolved shortly thereafter
- Right upper quadrant Doppler ultrasound 4 days after completion of thrombolysis showed normal waveforms and widely patent hepatic, portal, and splenic vasculature
- Patient was discharged home later that day tolerating a normal diet and without pain

"EKOS™ was an integral component in the efficient and thorough treatment of challenging extensive portomesenteric thrombus with prompt restoration of normal antegrade flow."

– Jason Smith, MD

Imagine where we can go.

Indications for use: The EkoSonic™ Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic™ Endovascular System is CE Marked for the treatment of pulmonary embolism with a ≥50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥25 mmHg) or echocardiographic evaluation. **Contraindications:** Not designed for peripheral vasculature dilation purposes. This system is contraindicated when, in the medical judgment of the physician, such a procedure may compromise that patient's condition. Such conditions include but are not limited to: • Tortuous vascular anatomy compromising safe introduction of endovascular equipment • Conditions associated with increased risk of bleeding. See device instructions for use for complete prescribing information http://ekoscorp.com/international_enter.htm#Resources

EKOS, the EKOS logo, Acoustic Pulse Thrombolysis and EkoSonic are trademarks of EKOS Corporation, a BTG International group company. EKOS is a registered trademark in the US, EU and certain other territories. 'Imagine where we can go', BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. All rights reserved. © 2015 EKOS Corporation. GXUS-EKO-2015-0211



btg-im.com